Loading...
XOSL
PCIB
Market cap5mUSD
Apr 30, Last price  
1.46NOK
1D
-2.67%
1Q
19.67%
Jan 2017
-89.52%
IPO
-84.78%
Name

PCI Biotech Holding ASA

Chart & Performance

D1W1MN
P/E
—
P/S
8.09
EPS
—
Div Yield, %
—
Shrs. gr., 5y
0.04%
Rev. gr., 5y
-2.15%
Revenues
7m
+125.25%
7,367,0008,612,00010,444,0007,423,000000000000002,990,0006,735,000
Net income
-16m
L-19.19%
-11,375,000-15,015,000-13,940,000-13,749,000-25,259,000-27,608,000-35,840,000-31,922,000-32,184,000-42,841,000-34,780,000-89,252,000-72,636,000-88,480,000-53,743,000-20,315,000-16,417,000
CFO
-14m
L-8.10%
-9,409,000-16,836,000-10,591,000-19,049,000-24,354,000-28,593,000-31,674,000-32,841,000-35,693,000-30,620,000-31,079,000-83,471,000-77,391,000-68,307,000-59,042,000-14,970,000-13,758,000
Earnings
May 23, 2025

Profile

PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in Phase I clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin. The company has collaborative research programs with Bavarian Nordic, BioNTech, Phio Pharmaceuticals, DCprime, eTheRNA immunotherapies, IMV, and Aposense. PCI Biotech Holding ASA is based in Oslo, Norway.
URL
https://www.pcibiotech.no/
IPO date
Jun 18, 2008
Employees
6
Domiciled in
NO
Incorporated in
NO

Valuation

Title
NOK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
6,735
125.25%
2,990
 
Cost of revenue
24,690
25,231
61,830
Unusual Expense (Income)
NOPBT
(17,955)
(22,241)
(61,830)
NOPBT Margin
Operating Taxes
(1,352)
Tax Rate
NOPAT
(17,955)
(22,241)
(60,478)
Net income
(16,417)
-19.19%
(20,315)
-62.20%
(53,743)
-39.26%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
336
319
443
Long-term debt
336
319
1,097
Deferred revenue
Other long-term liabilities
33
Net debt
(26,397)
(40,545)
(54,427)
Cash flow
Cash from operating activities
(13,758)
(14,970)
(59,042)
CAPEX
Cash from investing activities
Cash from financing activities
(357)
(442)
(678)
FCF
(17,968)
(20,963)
(54,393)
Balance
Cash
27,069
41,183
55,967
Long term investments
Excess cash
26,732
41,034
55,967
Stockholders' equity
1,119
1,119
57,402
Invested Capital
22,670
38,276
2,206
ROIC
ROCE
EV
Common stock shares outstanding
37,311
37,326
37,326
Price
1.19
-43.33%
2.10
2.44%
2.05
-85.26%
Market cap
44,401
-43.36%
78,385
2.44%
76,518
-85.26%
EV
18,004
37,840
22,091
EBITDA
(17,652)
(21,870)
(55,424)
EV/EBITDA
Interest
160
127
Interest/NOPBT